Fig. 6: Stereopure oligonucleotide protects against glutamate toxicity in C9-ALS motor neurons. | Nature Communications

Fig. 6: Stereopure oligonucleotide protects against glutamate toxicity in C9-ALS motor neurons.

From: Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models

Fig. 6

Schematic representation of experimental conditions in C9-ALS motor neuron assays for experiment 1 (a) and experiment 2 (b). c Percentage change in neurite length (top) and neurite branching points (bottom) over time (days) for C9-ALS motor neurons treated as shown in panel a with the indicated oligonucleotide. Data are presented as mean ± SEM, n = 3. d Percentage change in neurite length (top) and neurite branching points (bottom) over time (days) for C9-ALS motor neurons treated as shown in panel b and with the indicated oligonucleotide. Data are presented as mean ± SEM, n = 3. e Representative images of C9-ALS motor neurons pre-treatment (day 3) or post (day 8) in the presence or absence of glutamate (Glu), with PBS, 10 μM NTC or 10 μM C9orf72-631. Scale bar is 400 μm. Images were taken every 12 h for all samples (n = 3 per time point). This experiment was performed twice. f Relative survival (luminescence) for C9-ALS motor neurons. Data are mean ± SD, n = 3. One-way ANOVA with Dunnett’s multiple comparisons. ***P = 0.0002, ns non-significant. This experiment was performed twice. Source data are provided as a Source Data file. PBS phosphate-buffered saline, NTC non-targeting control, Glu glutamate.

Back to article page